# Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

> **NCT02563093** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 208 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative
- **BIOLOGICAL:** Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation
- **BIOLOGICAL:** Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative
- **BIOLOGICAL:** Fluzone High-Dose vaccine, 2015-2016 formulation

## Key facts

- **NCT ID:** NCT02563093
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2015-12
- **Final completion:** 2016-07
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2016-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02563093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02563093, "Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02563093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*